Bristol-Myers Squibb’s Breyanzi is indicated for the treatment of relapsed or refractory large B-cell lymphoma patients. Credit: Coolcaesar at English Wikipedia / commons.wikimedia.org.

Japan has granted approval for Bristol-Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel; liso-cel) as second-line therapy to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients.

The treatment is indicated for usage in such patients irrespective of autologous hematopoietic stem-cell transplantation status.

Related Company Profiles

View all

This approval is based on clinical trial findings in subjects with r/r aggressive B-cell non-Hodgkin lymphoma following first-line therapy.

It comprises data from the international Phase III trials (JCAR017-BCM-003) in patients intended for autologous hematopoietic stem-cell transplantation, Phase II trials (017006) in the US in patients not intended for such transplantation and Phase II trials’ cohort 2 (JCAR017-BCM-001) in Japan and Europe. 

The randomised, controlled JCAR017-BCM003 trial is underway in 184 subjects with r/r aggressive B-cell non-Hodgkin lymphoma following first-line treatment.

See Also:

According to the interim analysis data from the trial, a statistically and clinically significant improvement in event-free survival (EFS), a primary endpoint, as well as progression-free survival (PFS) in subjects who received Breyanzi, were reported.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the Breyanzi group, the median PFS was observed to be 14.8 months versus 5.7 months for the standard therapy arm. 

Additionally, the overall safety profile of subjects treated with Breyanzi and who had previous treatment with one regimen was in line with subjects who received treatment with two regimens or more earlier.

A chimeric antigen receptor (CAR) T cell therapy acting on CD19, Breyanzi has a 4-1BB costimulatory domain. This domain boosts the CAR T cells’ expansion and persistence. 

Bristol Myers Squibb R&D Japan head Makoto Sugita said: “We are very pleased that Breyanzi has been approved for use in the second-line treatment of relapsed or refractory LBCL, regardless of whether autologous hematopoietic stem-cell transplantation is intended. 

“This approval is a major step forward for patients with refractory or relapsed LBCL who have undergone first-line therapy, as they may now benefit from a new treatment modality to bring them and their families more hope.”

In October this year, the company reported a 3% decline in total revenues to $11.2bn in the third quarter (Q3) of 2022.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.